Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

被引：0
|
作者：
Vedder, A. C.
Linthorst, G. E.
Houge, G.
Groener, J. E. M.
Ormel, E. E.
Bouma, B. J.
Aerts, J. M. F. G.
Hirth, A.
Hollak, C. E. M.
机构：
[1] AMC, Dept Intern Med Endocr Metab, Amsterdam, Netherlands
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] AMC, Dept Biochem Med, Amsterdam, Netherlands
[4] AMC, Dept Cardiol, Amsterdam, Netherlands
[5] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2007年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [1] Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
    Vedder, Anouk C.
    Linthorst, Gabor E.
    Houge, Gunnar
    Groener, Johannna E. M.
    Ormel, Els E.
    Bouma, Berto J.
    Aerts, Johannes M. F. G.
    Hirth, Asle
    Hollak, Carla E. M.
    PLOS ONE, 2007, 2 (07):
  • [2] AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE
    Costa, M. G.
    Santos, M.
    Senna, K.
    VALUE IN HEALTH, 2018, 21 : S439 - S440
  • [3] Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani, Antonio
    Riccio, Eleonora
    Sabbatini, Massimo
    GENETICS IN MEDICINE, 2015, 17 (01) : 21 - 23
  • [4] COST ANALYSIS FOR THE TREATMENT OF FABRY DISEASE WITH AGALSIDASE ALFA AND AGALSIDASE BETA IN COLOMBIA
    Londono, S.
    Pareja, M.
    Becerra, J.
    VALUE IN HEALTH, 2020, 23 : S693 - S693
  • [5] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
    Hollak, Carla E.
    Arends, Maarten
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry
    Oder, Daniel
    Watkinson, Oliver
    Bichet, Daniel
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic
    van Kuilenburg, Andre B.
    West, Michael L.
    Hughes, Derralynn A.
    Biegstraaten, Marieke
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S64 - S65
  • [6] Antibody measurement on switching from agalsidase alfa to agalsidase beta in the treatment of Fabry disease
    Peters, C.
    Burling, K.
    Deegan, P. B.
    ACTA PAEDIATRICA, 2008, 97 : 111 - 112
  • [7] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
    Arends, Maarten
    Biegstraaten, Marieke
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry M.
    Oder, Daniel
    Watkinson, Oliver T.
    Bichet, Daniel G.
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic M.
    van Kuilenburg, Andre B. P.
    West, Michael L.
    Hughes, Derralynn A.
    Hollak, Carla E. M.
    JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) : 351 - 358
  • [8] Agalsidase alfa: specific treatment for Fabry disease
    Mehta, A
    HOSPITAL MEDICINE, 2002, 63 (06): : 347 - 350
  • [9] Treatment outcome and safety of agalsidase alfa in Fabry disease: Data from FOS - The Fabry outcome survey
    Mehta, A.
    Beck, M.
    Linhart, A.
    Sunder-Plassmann, G.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 28 - 28
  • [10] Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta
    Mehta, Atul
    Beck, Michael
    Kampmann, Christoph
    Frustaci, Andrea
    Germain, Dominique P.
    Pastores, Gregory M.
    Sunder-Plassmann, Gere
    MOLECULAR GENETICS AND METABOLISM, 2008, 95 (1-2) : 114 - 115
12345